ストックスクリーナーアプリを入手
4.50
3.02%
-0.14
前日終値:
$4.64
開ける：
$4.6
24時間の取引高:
14,526
Relative Volume:
0.36
時価総額：
$41.07B
収益：
-
当期純損益:
-
株価収益率:
-6.3452
EPS:
-0.7092
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+5.88%
1か月 パフォーマンス:
+29.68%
6か月 パフォーマンス:
+219.15%
1年 パフォーマンス:
+139.35%
1日の値動き範囲:
$4.423
$4.60
1週間の範囲:
$4.19
$4.69
52週間の値動き範囲:
$1.001
$5.87
Alterity Therapeutics Ltd Adr Stock (ATHE) Company Profile
ATHE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATHE
Alterity Therapeutics Ltd Adr
|
4.50 | 62.91M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Alterity Therapeutics Ltd Adr Stock (ATHE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-03 | ダウングレード | The Benchmark Company | Speculative Buy → Hold |
| 2024-12-12 | 開始されました | Maxim Group | Buy |
Alterity Therapeutics Ltd Adr (ATHE) 最新ニュース
Alterity Therapeutics highlighted at MSA Congress - Investing.com
Alterity Therapeutics highlighted at MSA Congress By Investing.com - Investing.com India
Alterity Therapeutics reports Phase 2 data at MSA Congress - Investing.com
Alterity Therapeutics reports Phase 2 data at MSA Congress By Investing.com - Investing.com South Africa
Alterity shares new phase 2 data on MSA treatment - Investing.com
Alterity shares new phase 2 data on MSA treatment By Investing.com - Investing.com India
Alterity Therapeutics announces regulatory notice - Investing.com
Alterity Therapeutics completes placement - Investing.com
Alterity Therapeutics announces regulatory notice By Investing.com - Investing.com UK
Alterity Therapeutics completes placement By Investing.com - Investing.com UK
ATHEAlterity Therapeutics Ltd Latest Stock News & Market Updates - Stock Titan
Alterity Concludes Open-Label Trial Patient Visits - Investing.com
Alterity Therapeutics announces compliance notice - Investing.com
Alterity Therapeutics Issues Over 1 Billion New Shares - TipRanks
Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight - GlobeNewswire Inc.
Alterity Therapeutics raises A$40M in placement - TipRanks
Alterity secures funding to advance MSA drug development - Investing.com India
JPMorgan Ceases Substantial Holding in Alterity Therapeutics - TipRanks
Alterity Therapeutics announces trading halt - Investing.com
Alterity Therapeutics Initiates Trading Halt for Capital Raising Announcement - TipRanks
JPMorgan Becomes Substantial Holder in Alterity Therapeutics - TipRanks
Alterity Therapeutics reports compliance with Takeovers Panel By Investing.com - Investing.com South Africa
Alterity Therapeutics reports compliance with Takeovers Panel - Investing.com
Alterity Therapeutics Discloses Equity Derivative Positions of Point72 - TipRanks
Alterity Therapeutics announces securities notice - Investing.com
Alterity Therapeutics Completes Significant Share Issuance - TipRanks
Alterity Therapeutics Quotes Over 164 Million Securities on ASX - TipRanks
Alterity Therapeutics announces ATH434 Phase 2 trial results - MSN
Alterity Therapeutics Announces Major Securities Placement - TipRanks
Alterity Therapeutics Secures Funding to Advance Neurodegenerative Drug Development - TipRanks
Alterity Therapeutics Reports Promising Phase 2 Results for MSA Drug ATH434 - TipRanks
Alterity Therapeutics Initiates Trading Halt Pending Phase II Trial Results - TipRanks
Predictive Oncology Inc (NASDAQ: POAI) Stock Is A Good Option To Consider - Stocks Register
Alterity Therapeutics reports quarterly activities - Investing.com
Alterity Therapeutics reports quarterly activities By Investing.com - Investing.com UK
Alterity Therapeutics Advances ATH434 Clinical Trials with Promising Data - TipRanks
Alterity Therapeutics Expands ASX Quoted Securities - TipRanks
Alterity Therapeutics Reports Key Advances and Anticipates Milestones in 2025 - TipRanks
Alterity Therapeutics Highlights Key Milestones in Neurodegenerative Disease Pipeline - TipRanks
Opthea reports positive Phase 1b DME trial results - Investing.com
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns - Stockhead
Alterity Therapeutics reports annual general meeting results - Investing.com
Alterity Therapeutics announces change in company secretary - Investing.com
Opthea adds Kathy Connell to Board of Directors - Investing.com
Alterity Therapeutics to join Maxim Healthcare Summit - Investing.com
Check Up: Aussie biotech Avarax on the verge of peanut allergy cure; and recent ASX health winners - Stockhead
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money ... - Stockhead
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) - PR Newswire
ASE Technology Holding Co., Ltd. American Depositary Shares (each representing (NY: ASX - Financial Content
Alterity Therapeutics Ltd Adr (ATHE) 財務データ
Alterity Therapeutics Ltd Adr (ATHE) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
3.98%
1.32%
大文字化:
|
ボリューム (24 時間):